Invesco’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13M Sell
173,019
-4,154
-2% -$267K ﹤0.01% 1766
2026
Q1
$9.99M Buy
177,173
+8,448
+5% +$550K ﹤0.01% 1830
2025
Q4
$13.5M Buy
168,725
+4,793
+3% +$322K ﹤0.01% 1672
2025
Q3
$7.99M Buy
163,932
+55,282
+51% +$3.42M ﹤0.01% 1967
2025
Q2
$8.11M Buy
108,650
+3,005
+3% +$199K ﹤0.01% 1918
2025
Q1
$6.71M Buy
105,645
+9,654
+10% +$657K ﹤0.01% 2017
2024
Q4
$7.49M Sell
95,991
-6,008
-6% -$483K ﹤0.01% 2034
2024
Q3
$8.2M Sell
101,999
-15,082
-13% -$1.22M ﹤0.01% 1948
2024
Q2
$9.69M Buy
117,081
+18,017
+18% +$1.58M ﹤0.01% 1810
2024
Q1
$8.46M Sell
99,064
-616,804
-86% -$48.4M ﹤0.01% 1914
2023
Q4
$61.2M Sell
715,868
-1,020
-0.1% -$88.2K 0.01% 922
2023
Q3
$64.2M Sell
716,888
-63,305
-8% -$5.65M 0.02% 861
2023
Q2
$66.4M Buy
780,193
+407,445
+109% +$34.4M 0.02% 849
2023
Q1
$30.8M Buy
372,748
+252,906
+211% +$20.5M 0.01% 1155
2022
Q4
$9.43M Buy
119,842
+6,998
+6% +$562K ﹤0.01% 1885
2022
Q3
$8.35M Buy
112,844
+9,239
+9% +$663K ﹤0.01% 1915
2022
Q2
$6.75M Buy
103,605
+8,979
+9% +$531K ﹤0.01% 2116
2022
Q1
$5.98M Buy
94,626
+19,711
+26% +$1.07M ﹤0.01% 2284
2021
Q4
$3.97M Buy
74,915
+1,087
+1% +$66.2K ﹤0.01% 2513
2021
Q3
$5.21M Sell
73,828
-1,602
-2% -$101K ﹤0.01% 2362
2021
Q2
$5.03M Sell
75,430
-122,672
-62% -$8.68M ﹤0.01% 2421
2021
Q1
$22M Buy
198,102
+14,477
+8% +$1.79M 0.01% 1471
2020
Q4
$21.8M Buy
183,625
+34,093
+23% +$3.67M 0.01% 1389
2020
Q3
$13M Sell
149,532
-217,407
-59% -$19M ﹤0.01% 1521
2020
Q2
$32.9M Sell
366,939
-477,007
-57% -$48.2M 0.01% 1080
2020
Q1
$84.1M Buy
843,946
+127,502
+18% +$13.8M 0.04% 569
2019
Q4
$82.3M Sell
716,444
-46,676
-6% -$5.65M 0.03% 763
2019
Q3
$96.3M Buy
763,120
+327,528
+75% +$41.6M 0.03% 673
2019
Q2
$52.4M Buy
435,592
+381,196
+701% +$37.5M 0.01% 1013
2019
Q1
$4.76M Sell
54,396
-194,830
-78% -$17.7M ﹤0.01% 2039
2018
Q4
$24.9M Buy
249,226
+58,800
+31% +$6.18M 0.01% 1044
2018
Q3
$21.8M Buy
190,426
+23,970
+14% +$2.48M 0.01% 1220
2018
Q2
$14.9M Sell
166,456
-175,252
-51% -$14.8M ﹤0.01% 1414
2018
Q1
$25M Sell
341,708
-20,061
-6% -$1.38M 0.01% 1054
2017
Q4
$21M Buy
361,769
+184,395
+104% +$9.71M 0.01% 1185
2017
Q3
$7.96M Buy
177,374
+976
+0.6% +$40.5K ﹤0.01% 1703
2017
Q2
$6.97M Buy
176,398
+13,019
+8% +$535K ﹤0.01% 1754
2017
Q1
$6.63M Buy
163,379
+2,796
+2% +$109K ﹤0.01% 1796
2016
Q4
$6.46M Sell
160,583
-11,840
-7% -$446K ﹤0.01% 1809
2016
Q3
$6.24M Sell
172,423
-121,872
-41% -$4.18M ﹤0.01% 1833
2016
Q2
$8.53M Buy
294,295
+52,848
+22% +$1.6M ﹤0.01% 1526
2016
Q1
$8.45M Buy
241,447
+40,751
+20% +$1.32M ﹤0.01% 1507
2015
Q4
$6.47M Buy
200,696
+9,883
+5% +$321K ﹤0.01% 1706
2015
Q3
$6.17M Sell
190,813
-170,813
-47% -$6.43M ﹤0.01% 1718
2015
Q2
$15M Sell
361,626
-335,799
-48% -$14.2M 0.01% 1344
2015
Q1
$31.3M Sell
697,425
-560
-0.1% -$23.4K 0.01% 1011
2014
Q4
$26.1M Sell
697,985
-33,624
-5% -$1.23M 0.01% 1078
2014
Q3
$25.5M Sell
731,609
-16,076
-2% -$574K 0.01% 1091
2014
Q2
$26.4M Sell
747,685
-15,291
-2% -$511K 0.01% 1099
2014
Q1
$24.9M Buy
762,976
+10,144
+1% +$388K 0.01% 1103
2013
Q4
$31.7M Buy
752,832
+24,816
+3% +$1.02M 0.01% 1016
2013
Q3
$29M Buy
728,016
+44,727
+7% +$1.88M 0.01% 1007
2013
Q2
$28.3M Buy
+683,289
New +$27.7M 0.01% 980

Other funds holding HAE

Invesco's HAE Position: Q2 2026 in Review

Invesco reduced its Haemonetics (HAE) stake by 2.3% in Q2 2026, selling an estimated $267K and leaving 173,019 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

Invesco first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $96.3M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Invesco held 173,019 shares of Haemonetics worth $13M as of Q2 2026.
  • Invesco sold 4,154 Haemonetics shares in Q2 2026, an estimated $267K.
  • Haemonetics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1766 holding.
  • Invesco first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • Invesco's Haemonetics position peaked at $96.3M in Q3 2019.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.